| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000030316 |
| Receipt No. | R000034474 |
| Public title | investigator initiated study of long-term treatment of Rhododenol-induced Leukoderma with Bimaprost |
| Date of disclosure of the study information | 2017/12/12 |
| Last modified on | 2019/03/12 (Ver. 3) |
| Basic information | ||
| Public title | investigator initiated study of long-term treatment of Rhododenol-induced Leukoderma with Bimaprost | |
| Acronym | investigator initiated study of long-term treatment of Rhododenol-induced Leukoderma with Bimaprost | |
| Scientific Title | investigator initiated study of long-term treatment of Rhododenol-induced Leukoderma with Bimaprost | |
| Scientific Title:Acronym | investigator initiated study of long-term treatment of Rhododenol-induced Leukoderma with Bimaprost | |
| Region |
|
|
| Condition | ||
| Condition | Rhododenol-induced Leukoderma | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Explore the efficacy and safety of long-term treatment of Rhododenol-induced Leukoderma with Bimaprost |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Degree of pigmentation after twelve months application of Bimatoprost on target region. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Self control |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Bimatoprost would be applied on the target region. The number of times to apply on the skin would follow the same number of times at the end of previous study "investigator initiated study of Rhododenol-induced Leukoderma". | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Patients diagnosed as Rhododenol-induced Leukoderma according to diagnostic criteria of Japanese Dermatology Association (meeting all contents of essential diagnostic criteria and meeting at least one content of minor diagnostic criteria)
a) essential diagnostic criteria i) Used Rhododenol containing cosmetics ii) Not having Leukoderma before using Rhododenol containing cosmetics. Complete or incomplete depigmented area emerged after use of Rhododenol containing cosmetics on mostly Rhododenol applied area. b) Minor diagnostic criteria i) The enlargement of Leukoderma stopped within a month after withdrawal of Rhododenol containing cosmetics. ii) After withdrawal of Rhododenol containing cosmetics, at least part of Leukoderma became re-pigmented. 2) The participant of the previous study and who also completed the observation period. 3) From the point of view of the efficacy and safety, those who were considered resonable by pricipal investigator or sub-investigator to be included in the subsequent study. 4) Those subjects who want to participate in the subsequent study after completing the previous study. 5) All participants are fully explained about the aim, content and expected side effects of the study. After confirming the participants' understanding, written informed consent is taken under their free will. |
|||
| Key exclusion criteria | 1) Age under twenty years old at the time of inforomed consent.
2) Those who were suspected of concomitant vitiligo vulgaris. 3) Those who show skin problems such as erythema at the site of target region. 4) Those subjects who were considered by the principal investigator or sub-investigator to be showing skin problem which might be related to previous study. 5) Those subjects who were considered by the principal investigator or sub-investigator to be difficult to comply with compliance. 6) Those who show allagic reaction against Bimatoprost. 7) Those women who are pregnant or possibly pregnant or during lactation or those who cannot agree with contraception during the study. 8) Those otherwise principal physician considered unsuitable to include in this study. |
|||
| Target sample size | 10 | |||
| Research contact person | |||||||
| Last name of lead principal investigator |
|
||||||
| Organization | Teikyo University | ||||||
| Division name | Institute of Medical Mycology | ||||||
| Zip code | |||||||
| Address | 359 Otsuka, Hachioji, Tokyo 192-0395 JAPAN 192-0395, Japan | ||||||
| TEL | 042-678-3256 | ||||||
| watanabe@med.teikyo-u.ac.jp | |||||||
| Public contact | |||||||
| 1st name of contact person |
|
||||||
| Organization | Teikyo University School of Medicine | ||||||
| Division name | Department of Dermatology | ||||||
| Zip code | |||||||
| Address | 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8601, Japan | ||||||
| TEL | 03-3964-1211 | ||||||
| Homepage URL | |||||||
| tada@df6.so-net.ne.jp | |||||||
| Sponsor | |
| Institute | Teikyo University School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Kanebo Cosmetics Inc |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 帝京大学医学部附属病院 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034474 |